339 related articles for article (PubMed ID: 20062090)
1. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
4. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
5. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
Willems E; Baron F; Seidel L; Frère P; Fillet G; Beguin Y
Bone Marrow Transplant; 2010 Apr; 45(4):689-93. PubMed ID: 19718063
[TBL] [Abstract][Full Text] [Related]
6. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
Couriel DR; Saliba RM; Giralt S; Khouri I; Andersson B; de Lima M; Hosing C; Anderlini P; Donato M; Cleary K; Gajewski J; Neumann J; Ippoliti C; Rondon G; Cohen A; Champlin R
Biol Blood Marrow Transplant; 2004 Mar; 10(3):178-85. PubMed ID: 14993883
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
[TBL] [Abstract][Full Text] [Related]
8. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
9. Cytokine gene expression in peripheral blood mononuclear cells and alloreactivity in hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Dickmeiss E; Vindeløv LL
Biol Blood Marrow Transplant; 2006 Jan; 12(1):48-60. PubMed ID: 16399568
[TBL] [Abstract][Full Text] [Related]
10. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
12. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
13. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
15. Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.
Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Herens C; DePrijck B; Fillet G; Beguin Y
Bone Marrow Transplant; 2003 Oct; 32(8):829-34. PubMed ID: 14520430
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.
Schetelig J; Kröger N; Held TK; Thiede C; Krusch A; Zabelina T; Dubiel M; Rick O; Bornhäuser M; Ehninger G; Zander AR; Siegert W
Haematologica; 2002 Mar; 87(3):299-305. PubMed ID: 11869943
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.
Gerull S; Goerner M; Benner A; Hegenbart U; Klein U; Schaefer H; Goldschmidt H; Ho AD
Bone Marrow Transplant; 2005 Dec; 36(11):963-9. PubMed ID: 16184182
[TBL] [Abstract][Full Text] [Related]
18. Acute renal failure after nonmyeloablative stem cell transplantation in adults.
Kersting S; Dorp SV; Theobald M; Verdonck LF
Biol Blood Marrow Transplant; 2008 Jan; 14(1):125-31. PubMed ID: 18158969
[TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
